Menu Search
Equities

MaxCyte Inc

MXCT:NSQ

MaxCyte Inc

Actions
  • Price (USD)3.55
  • Today's Change0.10 / 2.90%
  • Shares traded516.97k
  • 1 Year change-21.11%
  • Beta1.3861
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year MaxCyte Inc's revenues fell -6.72% from 44.26m to 41.29m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 23.57m to a larger loss of 37.92m.
Gross margin85.98%
Net profit margin-78.37%
Operating margin-101.74%
Return on assets-13.87%
Return on equity-16.00%
Return on investment-14.86%
More ▼

Cash flow in USDView more

In 2023, MaxCyte Inc increased its cash reserves by 320.30%, or 35.44m. Cash Flow from Investing totalled 54.98m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 21.69m for operations while cash generated from financing totalled 2.14m.
Cash flow per share-0.3006
Price/Cash flow per share--
Book value per share2.03
Tangible book value per share2.03
More ▼

Balance sheet in USDView more

MaxCyte Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 46.51m.
Current ratio9.81
Quick ratio9.22
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.